Cargando…

Malignant pleural mesothelioma co-opts BCL-X(L) and autophagy to escape apoptosis

Escape from programmed cell death is a hallmark of cancer. In this study, we investigated the anti-apoptotic mechanisms and explored the therapeutic potential of BCL-2 homology domain-3 (BH3) mimetics in malignant pleural mesothelioma (MPM), a lethal thoracic malignancy with an extreme dearth of tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Duo, Liang, Shun-Qing, Yang, Zhang, Yang, Haitang, Bruggmann, Rémy, Oberhaensli, Simone, Berezowska, Sabina, Marti, Thomas M., Hall, Sean R. R., Dorn, Patrick, Kocher, Gregor J., Schmid, Ralph A., Peng, Ren-Wang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050302/ https://www.ncbi.nlm.nih.gov/pubmed/33859162 http://dx.doi.org/10.1038/s41419-021-03668-x

Ejemplares similares

Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
por: Xu, Duo, et al.
Publicado: (2019)

Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma
por: Xu, Duo, et al.
Publicado: (2018)

Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2022)

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2023)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
por: Xu, Duo, et al.
Publicado: (2020)

Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma
por: Karatkevich, Darya, et al.
Publicado: (2022)

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer
por: Wang, Limei, et al.
Publicado: (2021)

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2020)

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021)

Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature
por: Schumann, Sven Oliver, et al.
Publicado: (2021)

Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines
por: Cortes-Dericks, Lourdes, et al.
Publicado: (2016)

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
por: Gao, Yanyun, et al.
Publicado: (2021)

Operative versus non-operative management of rib fractures in flail chest after cardiopulmonary resuscitation manoeuvres
por: Dorn, Patrick, et al.
Publicado: (2022)

NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma
por: Yang, Haitang, et al.
Publicado: (2021)

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
por: Yang, Haitang, et al.
Publicado: (2019)

Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer
por: Liang, S-Q, et al.
Publicado: (2015)

Interleukin‐5‐producing malignant pleural mesothelioma with eosinophilic pleural effusion
por: Takeuchi, Eiji, et al.
Publicado: (2020)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Functional and molecular characterization of PD1(+) tumor-infiltrating lymphocytes from lung cancer patients
por: Lipp, Jesse J., et al.
Publicado: (2022)

Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549()
por: Tièche, Colin Charles, et al.
Publicado: (2018)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?
por: Gao, Yanyun, et al.
Publicado: (2022)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
por: Yang, Zhang, et al.
Publicado: (2022)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_ut4gt8ig7oett33i923ferq2o0